Hirshberg, Boaz

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 3,470

Assessment of Human Pancreatic Islet Architecture and Composition by Laser Scanning Confocal Microscopy

Brissova, M., Fowler, M. J., Nicholson, W. E., Chu, A., Hirshberg, B., Harlan, D. M., & Powers, A. C. (2005) · Journal of Histochemistry & Cytochemistry

Pancreatic function and diabetesDiabetes and associated disorders

Cited by 797

Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial

Scirica, B. M., Braunwald, E., Raz, I., Cavender, M. A., Morrow, D. A., Jarolim, P., Udell, J. A., Mosenzon, O., Im, K., Umez-Eronini, A. A., et al. (2014) · Circulation

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 725

Glucagon-Like Peptide 1 Inhibits Cell Apoptosis and Improves Glucose Responsiveness of Freshly Isolated Human Islets

Farilla, L., Bulotta, A., Hirshberg, B., Li Calzi, S., Khoury, N., Noushmehr, H., Bertolotto, C., Di Mario, U., Harlan, D. M., & Perfetti, R. (2003) · Endocrinology

Pancreatic function and diabetesDiabetes Treatment and Management

Cited by 664

Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study

Nahra, R., Wang, T., Gadde, K. M., Oscarsson, J., Stumvoll, M., Jermutus, L., Hirshberg, B., & Ambery, P. (2021) · Diabetes Care

Diabetes Treatment and ManagementLiver Disease Diagnosis and Treatment

Cited by 323

MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study

Ambery, P., Parker, V. E., Stumvoll, M., Posch, M. G., Heise, T., Plum-Moerschel, L., Tsai, L.-F., Robertson, D., Jain, M., Petrone, M., et al. (2018) · The Lancet

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 298

Forty-Eight-Hour Fast: The Diagnostic Test for Insulinoma

Hirshberg, B., Livi, A., Bartlett, D. L., Libutti, S. K., Alexander, H. R., Doppman, J. L., Skarulis, M. C., & Gorden, P. (2000) · The Journal of Clinical Endocrinology & Metabolism

Neuroendocrine Tumor Research AdvancesPancreatic function and diabetes

Cited by 256

Efficacy, safety, and mechanistic insights of cotadutide, a dual receptor glucagon-like peptide-1 and glucagon agonist

Parker, V. E. R., Robertson, D., Wang, T., Hornigold, D. C., Petrone, M., Cooper, A. T., Posch, M. G., Heise, T., Plum-Moerschel, L., Schlichthaar, H., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 123

The design and rationale of the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus–Thrombolysis in Myocardial Infarction (SAVOR-TIMI) 53 Study

Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Price, D. L., Chen, R., Udell, J., et al. (2011) · American Heart Journal

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 106

Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial

Leiter, L. A., Teoh, H., Braunwald, E., Mosenzon, O., Cahn, A., Kumar, K. M. P., Smahelova, A., Hirshberg, B., Stahre, C., Frederich, R., et al. (2015) · Diabetes Care

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 87

MEDI0382, a GLP‐1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a single‐dose, healthy‐subject, randomized, Phase 1 study

Ambery, P. D., Klammt, S., Posch, M. G., Petrone, M., Pu, W., Rondinone, C., Jermutus, L., & Hirshberg, B. (2018) · British Journal of Clinical Pharmacology

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 75

GDF8 and activin A are the key negative regulators of muscle mass in postmenopausal females: a randomized phase I trial

Gonzalez Trotter, D., Donahue, S., Wynne, C., Ali, S., Parasoglou, P., Boyapati, A., Mohammadi, K., Musser, B. J., Meier, P., Mastaitis, J., et al. (2025) · Nature Communications

Muscle Physiology and DisordersTGF-β signaling in diseases

Cited by 23